Citadel Advisors’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-94,100
| Closed | -$10M | – | 14198 |
|
|
2025
Q3 | $10M | Sell |
94,100
-26,100
| -22% | -$2.73M | ﹤0.01% | 3264 |
|
|
2025
Q2 | $11.4M | Buy |
120,200
+27,000
| +29% | +$2M | ﹤0.01% | 2845 |
|
|
2025
Q1 | $5.92M | Buy |
93,200
+22,600
| +32% | +$1.35M | ﹤0.01% | 3617 |
|
|
2024
Q4 | $3.28M | Buy |
70,600
+54,500
| +339% | +$2.05M | ﹤0.01% | 4691 |
|
|
2024
Q3 | $463K | Sell |
16,100
-124,000
| -89% | -$3.05M | ﹤0.01% | 8430 |
|
|
2024
Q2 | $2.03M | Buy |
140,100
+122,400
| +692% | +$1.79M | ﹤0.01% | 5279 |
|
|
2024
Q1 | $285K | Sell |
17,700
-1,300
| -7% | -$22.5K | ﹤0.01% | 9562 |
|
|
2023
Q4 | $378K | Buy |
19,000
+11,100
| +141% | +$164K | ﹤0.01% | 8684 |
|
|
2023
Q3 | $129K | Sell |
7,900
-11,300
| -59% | -$218K | ﹤0.01% | 10575 |
|
|
2023
Q2 | $406K | Buy |
19,200
+10,700
| +126% | +$228K | ﹤0.01% | 8384 |
|
|
2023
Q1 | $171K | Sell |
8,500
-156,600
| -95% | -$3.38M | ﹤0.01% | 10437 |
|
|
2022
Q4 | $4.31M | Buy |
165,100
+92,800
| +128% | +$1.24M | ﹤0.01% | 4111 |
|
|
2022
Q3 | $739K | Buy |
72,300
+26,100
| +56% | +$220K | ﹤0.01% | 7649 |
|
|
2022
Q2 | $194K | Buy |
46,200
+31,300
| +210% | +$134K | ﹤0.01% | 10728 |
|
|
2022
Q1 | $74K | Buy |
+14,900
| New | +$86.7K | ﹤0.01% | 12538 |
|
|
2021
Q1 | – | Sell |
-12,100
| Closed | -$85K | – | 13766 |
|
|
2020
Q4 | $85K | Buy |
+12,100
| New | +$81.7K | ﹤0.01% | 10315 |
|
Other funds holding VRNA
Citadel Advisors's VRNA Position: Q4 2025 in Review
Citadel Advisors sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 461,869 shares — an estimated $49.3M sold.
Citadel Advisors first reported a position in VRNA in Q1 2019 and held it in 16 quarters. The position peaked at $132M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- Citadel Advisors reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 461,869 Verona Pharma shares in Q4 2025, an estimated $49.3M.
- Citadel Advisors first reported a position in Verona Pharma in Q1 2019 and held it in 16 quarters.
- Citadel Advisors's Verona Pharma position peaked at $132M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.